Tag: Saroglitazar
Zydus Therapeutics announces positive phase 2b/3 results for Saroglitazar in primary...
EPICS-III trial met primary and key secondary endpoints, with Saroglitazar demonstrating significant efficacy, good tolerability, and paving the way for a planned U.S. regulatory submission in early 2026
Zydus gets DCGI nod for Saroglitazar Mg for the treatment of...
It becomes the first medicine for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD), a spectrum ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), which has the propensity to progress to liver cirrhosis....................